Update on the optimal use of voriconazole for invasive fungal infections.

Authors:
Lat A; Thompson GR.

Journal:
Infect Drug Resist

Publication Year: 2011

DOI:
10.2147/IDR.S12714

PMCID:
PMC3108750

PMID:
21694908

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Infect Drug Resist

Abbreviation: Infect Drug Resist

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.
Axler E; Lipner SR. (2024) - Transparency Score: 3/6
Antimicrobial Resistance of <i>Clostridioides difficile</i> in Children from a Tertiary Pediatric H…
Li X; Wang Y; Cao R and 6 more (2024) - Transparency Score: 4/6
Antimicrobial Resistance Patterns of Staphylococcus Aureus Isolated at a General Hospital in Vietna…
An NV; Hai LHL; Luong VH and 14 more (2024) - Transparency Score: 3/6
Antimicrobial Use-Related Problems Among Hospitalized Pediatric Patients: A Prospective Observation…
Gidey K; Aregawi SG; Hailu BY and 2 more (2024) - Transparency Score: 3/6
Association Studies of Serum Levels of TNF- α, IL-10, IFN-γ and CXCL 5 with Latent Tuberculosis Inf…
Razbek J; Daken M; Chen Y and 7 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure: GRT has received research support from Pfizer, Merck & Co., and Basilea. AL has no conflicts of interest."

Evidence found in paper:

"Disclosure: GRT has received research support from Pfizer, Merck & Co., and Basilea. AL has no conflicts of interest."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025